Since sCD163, one of the activation markers of CD163+ TAMs [73], is a disease progression marker of CTCL [74], evaluation of stromal factors that stimulate and repolarize CD163+ TAMs is important, and the neutralization of stromal factors could be a target for CTCL therapy [72,75]. This evidence concerns the gene CD163 and primary cutaneous T-cell non-Hodgkin lymphoma.